179262-62-5Relevant academic research and scientific papers
Efficacy of Novel Syk-Kinase Inhibitors MT-SYK-03 and MT-SYK-322 in Cellular Models of Autoimmunity and Cancer
Rakitina, Tatiana V.,Zeifman, Alexey A.,Titov, Ilya Yu.,Svitanko, Igor V.,Lipkin, Aleksey V.,Stroylov, Viktor S.,Stroganov, Oleg V.,Novikov, Fedor N.,Chilov, Ghermes G.
, p. 287 - 289 (2012)
Novel rationally-designed Syk-kinase inhibitor MT-SYK-03 demonstrated equal potency with R406 (active metabolite of Fostamatinib, a phase III clinical trial candidate) in cellular models of autoimmunity and cancer with EC50 values in sub-micromolar range, while MT-SYK-322 was less active.
Quinazoline heterocyclic compounds as well as preparation method and application thereof
-
Paragraph 0099; 0100; 0101; 0102, (2017/07/19)
The invention provides quinazoline heterocyclic compounds as well as a preparation method and an application thereof and belongs to the field of medicinal chemistry. The structural formula is shown as a formula (I) in the specification, wherein R represents -H and -CH3; R is defined in the specification, 8,10-dichloro-2,3-dihydro-[1,4] dioxane [2,3-f] quinazoline (IX) is prepared firstly, and then R and R substitution are performed. The compounds can be applied as PI3K (phosphoinositide 3-kinase) inhibitors for treating cancer.
